Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Contraception. 2010 Jul;82(1):102-12. doi: 10.1016/j.contraception.2010.02.007. Epub 2010 Mar 29.
Women undergoing solid organ transplantation are advised to avoid pregnancy for up to 24 months following transplant surgery.
We conducted a systematic review of the literature, from database (PubMed) inception through February 2009, to evaluate evidence on the safety and effectiveness of contraceptive use among women having undergone solid organ transplantation.
From 643 articles, eight articles from seven studies satisfied review inclusion criteria; six articles pertained to kidney transplant patients, and two reported on liver transplant patients. Two reports of one prospective cohort of 36 kidney transplant recipients taking combined oral contraceptives (COCs) or using the transdermal contraceptive patch reported no significant changes in biochemical measures after 18 months of use for either group, although 13 women modified antihypertensive medication, and two women discontinued the study because of serious medical complications. Four case reports of five kidney recipients using intrauterine devices reported inconsistent findings, including both beneficial health effects and contraceptive failures. One retrospective, noncomparative study of 15 liver transplant recipients using COCs or the transdermal contraceptive patch found no significant changes in any biochemical measures obtained, no discontinuations or severe complications and no pregnancies after a 12-month follow up. One case report of a liver transplant recipient on cyclosporine and prednisone documented the development of cholestasis associated with high-dose (50 mcg ethinyl estradiol) COC use as treatment for heavy uterine bleeding.
Very limited evidence on COC and transdermal contraceptive patch use among kidney and liver transplant recipients indicated no pregnancies and no overall changes in biochemical measures. Excluding case reports, evidence on other contraceptive methods or contraception among other types of solid organ transplants was not identified.
女性在进行实体器官移植后,建议在移植手术后的 24 个月内避免怀孕。
我们对文献进行了系统回顾,从数据库(PubMed)建立到 2009 年 2 月,以评估女性进行实体器官移植后使用避孕措施的安全性和有效性的证据。
从 643 篇文章中,有 8 篇文章来自 7 项研究符合审查纳入标准;其中 6 篇涉及肾移植患者,2 篇报告了肝移植患者。两份报告是对 36 名接受联合口服避孕药(COC)或使用透皮避孕贴的肾移植受者的前瞻性队列的报告,两组在使用 18 个月后,生化指标均无显著变化,尽管 13 名女性改变了降压药物,2 名女性因严重医疗并发症而停止了研究。5 例肾移植患者使用宫内节育器的 4 例病例报告结果不一致,包括对健康有益的影响和避孕失败。15 例肝移植患者使用 COC 或透皮避孕贴的回顾性非对照研究发现,在 12 个月的随访中,没有任何生化指标发生显著变化,没有停药或严重并发症,也没有怀孕。1 例环孢素和泼尼松治疗的肝移植受者的病例报告记录了与高剂量(50 微克炔雌醇)COC 治疗重度子宫出血相关的胆汁淤积的发生。
关于肾和肝移植受者使用 COC 和透皮避孕贴的非常有限的证据表明没有怀孕,也没有生化指标的总体变化。不包括病例报告,也没有确定其他避孕方法或其他类型实体器官移植中的避孕的证据。